Fractyl Health

GUTS

Market cap $263M

Participants who lost 24% total body weight (>50 lbs.) on GLP-1 drugs maintained stable weight 6 months after GLP-1 discontinuation and single Revita treatment

BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of the Company, will be participating in a fireside chat at the 8th Annual Evercore Healthcare Conference, being held December 2-4, 2025, in Coral Gables, FL.

Fractyl Health, Inc. ( GUTS ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Brian Luque - Head of Investor Relations & Corporate Development Harith Rajagopalan - Co-Founder, CEO & Director Lisa Davidson - CFO & Treasurer Conference Call Participants Chi Meng Fong - BofA Securities, Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Division Michael Ulz - Morgan Stanley, Research Division Angela Qian - Canaccord Genuity Corp., Research Division Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good afternoon, and welcome to Fractyl Health Third Quarter 2025 Financial Results and Business Update Call.

Positive randomized 3-month REMAIN-1 Midpoint Cohort data showed single Revita procedure maintained weight loss after GLP-1 discontinuation; 6-month data expected in Q1 2026 6-month data from open-label REVEAL-1 Cohort expected in Q4 2025 Topline 6-month data from REMAIN-1 Pivotal Cohort and potential PMA filing expected in H2 2026 $83M in underwritten offerings expected to extend cash runway through upcoming clinical and regulatory milestones and into early 2027 Conference call today at 4:30 p.m. ET BURLINGTON, Mass.

BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the third quarter 2025 and provide business updates on Wednesday, November 12, 2025, at 4:30 p.m. ET.

RJVA-002 achieved ~30% weight loss at five weeks in a translational obesity model; weight loss not yet plateaued Preclinical results show that a single point-in-time treatment with RJVA-002 has the potential to achieve significant weight loss that can match or exceed best-in-class chronic drug therapy BURLINGTON, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced potent new preclinical data from RJVA-002, the second candidate from the Company's Rejuva® Smart GLP-1™ platform, at the 2025 Cell & Gene Meeting on the Mesa.

Fractyl Health delivered best-case results from its REMAIN-1 trial, with Revita patients continuing weight loss after GLP-1 discontinuation while placebo significantly rebounded. GUTS is still ~$230 million market cap, given de-risked Revita data and a robust cash position following recent financings. Revita's unique, durable weight loss profile and minimal side effects position it as a one-time solution for GLP-1 discontinuation, addressing a major market need.

Fractyl Health, Inc. - Special Call Company Participants Brian Luque Harith Rajagopalan - Co-Founder, CEO & Director Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Whitney Ijem - Canaccord Genuity Corp., Research Division Jason Gerberry - BofA Securities, Research Division Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division William Wood - B.

Fractyl Health said its experimental outpatient procedure helped preserve weight loss after discontinuation of a GLP-1 drug, sending the company's shares 23% higher in premarket trading on Friday.

Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock BURLINGTON, Mass., September 26, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (“T2D”), today announced the pricing of an underwritten offering of 60 million shares of its common stock at a price of $1.00 per share.